- Conditions
- Child Abuse, Intimate Partner Violence, Secondary Prevention, Parenting
- Interventions
- Pregnant Moms' Empowerment Program, Reminiscing and Emotion Training, Pregnancy - Active Control, Enhanced Case Management
- Behavioral
- Lead sponsor
- University of Notre Dame
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Notre Dame, Indiana • Madison, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 228
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Transient Ischemic Attack
- Interventions
- Telestroke
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 5
- States / cities
- Burnsville, Minnesota • Grand Rapids, Minnesota • Hibbing, Minnesota + 2 more
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- cyclosporine ophthalmic emulsion, placebo
- Drug · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more
- Conditions
- Stroke, Transient Ischemic Attack
- Interventions
- COMPASS Intervention
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,024 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 40
- States / cities
- Albemarle, North Carolina • Asheville, North Carolina • Chapel Hill, North Carolina + 32 more
- Conditions
- Post-Traumatic Headache
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
- Conditions
- PTSD
- Interventions
- Behavioral Activation Therapeutic Exposure (BATE)
- Behavioral
- Lead sponsor
- Charleston Research Institute
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 2
- States / cities
- Charleston, South Carolina
- Conditions
- Cancer
- Interventions
- fluconazole, itraconazole
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Saphenous Vein Graft Disease
- Interventions
- Aspirin, Ticagrelor
- Drug
- Lead sponsor
- Boca Raton Regional Hospital
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Boca Raton, Florida
- Conditions
- Post-Traumatic Headache
- Interventions
- gammaCore Sapphire, sham gammaCore Sapphire
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Secondary Myelofibrosis, Small Intestine Cancer
- Interventions
- anti-thymocyte globulin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, methotrexate, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Duarte, California
- Conditions
- Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Aplastic Anemia, Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Cytomegalovirus Infection, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extramedullary Plasmacytoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Isolated Plasmacytoma of Bone, Mast Cell Leukemia, Meningeal Chronic Myelogenous Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Primary Systemic Amyloidosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Secondary Myelofibrosis, Splenic Marginal Zone Lymphoma, Stage 0 Chronic Lymphocytic Leukemia, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Waldenstrom Macroglobulinemia
- Interventions
- infection prophylaxis and management, laboratory biomarker analysis, flow cytometry, DNA analysis, RNA analysis, management of therapy complications, ganciclovir, valganciclovir, foscarnet sodium, antiviral therapy, polymerase chain reaction, protein expression analysis
- Procedure · Other · Genetic + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Post Traumatic Headache
- Interventions
- naratriptan HCl
- Drug
- Lead sponsor
- Cady, Roger, M.D.
- Individual
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 3
- States / cities
- Springfield, Missouri • Charlotte, North Carolina • Dallas, Texas
- Conditions
- Syncope, Vasovagal, Neurally-Mediated
- Interventions
- fludrocortisone acetate
- Drug
- Lead sponsor
- University of Calgary
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Nashville, Tennessee • Richmond, Virginia
- Conditions
- Cerebrovascular Accident, Hypertension
- Interventions
- aspirin, clopidogrel, Target of Blood Pressure, placebo
- Drug · Other
- Lead sponsor
- University of British Columbia
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 3,020 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 39
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 32 more
- Conditions
- Substance Use, Stress, Relation, Interpersonal, Bullying, Victimisation, Mental Health Issue, Sleep, Inadequate, Social Skills
- Interventions
- PeerLearning.net
- Behavioral
- Lead sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 924 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Eugene, Oregon
- Conditions
- Coronary Artery Disease
- Interventions
- Education
- Other
- Lead sponsor
- Jeffrey Kramer, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Chronic Pain, Acute Pain Due to Trauma, Posttraumatic Stress Disorder
- Interventions
- PTSD Coach mobile application
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Ischemic Stroke, CYP2C19 Polymorphism
- Interventions
- CYP2C19 Genotype
- Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Venous Thromboembolism, Secondary Prevention
- Interventions
- dabigatran etexilate
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 9
- States / cities
- Sacramento, California • Miami, Florida • Tampa, Florida + 6 more
- Conditions
- Secondary Prevention of Coronary Heart Disease
- Interventions
- PLUS, LITE
- Behavioral
- Lead sponsor
- The Miriam Hospital
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- HIV, AIDS
- Interventions
- MOVE Intervention, H4L Comparison Intervention
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 16 Years to 24 Years · Male only
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Chicago, Illinois • The Bronx, New York + 2 more
- Conditions
- Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
- Interventions
- Oral Vancomycin, Placebo
- Drug · Other
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Tampa, Florida
- Conditions
- Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
- Interventions
- Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab, Tucatinib
- Drug
- Lead sponsor
- Carey Anders, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
- Conditions
- Aggression
- Interventions
- Second Step Curriculum
- Behavioral
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 11 Years to 15 Years
- Enrollment
- 4,089 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Champaign, Illinois